Characteristics | Pre-Trastuzumab Era | Trastuzumab Era | p- value |
---|---|---|---|
n = 128 | n = 441 | ||
Age (years) | 0.017 | ||
<65 | 104 (81%) | 345 (78%) | |
≥ 65 | 24 (19%) | 96 (22%) | |
Median | 53 (26–81) | 55 (29–91) | |
M1 at diagnosis | <0.001 | ||
Yes | 5 (4%) | 113 (26%) | |
No | 115 (90%) | 256 (58%) | |
Unknown | 8 (6%) | 72 (16%) | |
Tumor grade | 0.084 | ||
1 | 0 (0%) | 13 (3%) | |
2 | 24 (19%) | 106 (24%) | |
3 | 95 (74%) | 315 (71%) | |
Unknown | 9 (7%) | 7 (2%) | |
Hormone receptor status | 0.83 | ||
ER+ | 51 (40%) | 180 (41%) | |
ER- | 68 (53%) | 249 (57%) | |
Unknown | 9 (7%) | 12 (3%) | |
HER2 status | <0.001 | ||
Positive | 33 (26%) | 176 (40%) | |
Negative | 87 (68%) | 212 (48%) | |
Unknown | 8 (6%) | 53 (12%) | |
Time from diagnosis to BM (years) | |||
Median | 3.3 | 2.3 | |
KPS at BM | 0.76 | ||
<70 | 47 (37%) | 170 (38%) | |
≥70 | 81 (63%) | 271 (62%) | |
Number of BM | 0.025 | ||
1 | 44 (34%) | 117 (27%) | |
2-3 | 23 (18%) | 73 (16%) | |
Multiple | 61 (48%) | 251 (57%) | |
Primary disease at BM | 0.007 | ||
Controlled | 104 (81%) | 305 (70%) | |
Uncontrolled | 24 (19%) | 135 (31%) | |
Extracranial disease at BM | 0.32 | ||
Brain only | 22 (17%) | 97 (22%) | |
Bone + brain | 22 (17%) | 76 (17%) | |
Visceral + brain +/−bone | 76 (59%) | 245 (57%) | |
Other | 8 (6%) | 23 (5%) | |
RPA at BM | 0.17 | ||
1 | 9 (7%) | 55 (12%) | |
2 | 72 (56%) | 219 (50%) | |
3 | 47 (37%) | 167 (39%) | |
Craniotomy | 0.037 | ||
Yes | 15 (12%) | 87 (20%) | |
No | 113 (88%) | 354 (80%) | |
Trastuzumab at BM* | |||
Yes | 0 (0%) | 150 (34%) | |
No | 128 (100%) | 26 (5%) | |
Hormonal therapy at BM* | <0.001 | ||
Yes | 72 (56%) | 100 (23%) | |
No | 56 (44%) | 341 (77%) | |
Chemotherapy at BM* | 0.032 | ||
Yes | 43 (34%) | 194 (44%) | |
No | 85 (66%) | 242 (55%) | |
Unknown | 0 (0%) | 5 (1%) |